Although oral chemotherapy is convenient, adherence and safety must be monitored, especially in older patients. Health care providers must recognize discordances in patient-centered care beliefs and collaboratively devise care plans. Researchers identified genes related to copper deficiency and explored their role in MM. Steroid-induced diabetes did not affect survival, but DM diagnosis at the time of MM diagnosis led to worse outcomes. Certain genetic markers predicted worse overall survival outcomes in a recent study. While other symptoms did emerge, the most common was worry. Could improving other symptoms lessen worry? Exercise is often recommended for patients with MM as part of a general well-being approach, but can it actually worsen QoL? Using carfilzomib instead of bortezomib improved progression-free and overall survival and reduced toxicity. The difference was significant, with patients who received AHSCT with residual clonal plasma cells having much lower OS. Though attrition rates increased, they were lower than previously reported. Four themes were identified from patient telephone interview responses that summarized the experience of living with MM. Patients reported higher levels of gastrointestinal, psychological, and dermatological side-effects than their providers did. Patients who remained MRD-negative for ≥12 months had better duration of response and progression-free survival. The HealthTree Foundation for Multiple Myeloma interviews Dr. Urvi Shah about IVIG. Fluorescence in situ hybridization can detect genetic abnormalities that allow stratification of disease risk. Only 2 patients experienced adverse events higher than grade 1 or 2, and response rates were high. Toxicity- and disease-related adverse outcomes can affect the quality of life in this high-exposure population. Non-Hispanic Black and Hispanic patients reported worse mental health and poorer sleep than their non-Hispanic White peers. Half of all patients in a synthesized analysis developed infections, and a quarter developed grade III/IV infections. Survey respondents described transportation, information, and scheduling barriers to treatment.